Shang et al. revealed that SMYD2 targeted Lys-370 of p53 and transcriptionally down-regulating activity of p53, which inhibited cell apoptosis and mediated cisplatin-resistant malignant phenotypes in NSCLC cells (Figure 2(h)) [37]. This evidence concerns the gene SMYD2 and non-small cell lung carcinoma.